葛兰素史克(GSK.US)血癌药物Blenrep重获FDA批准，将重返美国市场

Core Viewpoint - The approval of GSK's Blenrep by U.S. regulators marks a significant opportunity for the company to re-enter the largest pharmaceutical market after previously withdrawing the drug due to efficacy concerns [1][2] Group 1: Drug Approval and Market Potential - The U.S. FDA has approved GSK's Blenrep for use in combination with two other drugs for treating relapsed or treatment-resistant multiple myeloma patients [1] - This approval is accompanied by a risk mitigation plan to ensure proper usage and coordination among healthcare providers [1] - Industry research estimates that the sales potential for Blenrep could reach up to $2.6 billion following its approval [1] Group 2: Previous Withdrawal and New Research - GSK withdrew Blenrep from the market in 2022 due to its inability to demonstrate superiority over existing therapies [2] - The company subsequently explored combination therapies and found that the new regimen could reduce the risk of death by 42% compared to a drug sold by Johnson & Johnson [2]